Adagene Inc. (ADAG) research
Adagene Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.80
- As of
Kresmion compiles this page from ADAG's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Adagene Inc. (ADAG): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-25.
As of . Source: SEC EDGAR filings for ADAG. Method and limitations.
Share the ADAG intelligence card
See the full ADAG dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ADAG on one page. Preview it with sample data, then open it live with a free account.
Preview the ADAG dossierActive signals for ADAG
- highCONSENSUS_BUY
3 tracked funds increased ADAG this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +948% to ADAG (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +324% to ADAG (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in ADAG
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in ADAG
FREE, NO ACCOUNT
Every signal on ADAG, as it fires
New filings, 13F moves and cross asset signals on ADAG land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ADAG (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 005329107 · 2026Q2 | $2.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 005329107 · 2026Q2 | $615K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 005329107 · 2026Q2 | $50K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ADAG
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
ADAG against its peers
ADAG's operating margin of -279.5% ranks in the 50th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | ADAG | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.7M USD | 21.0M USD | 28 | 15 |
| Operating margin | -279.5% | -325.6% | 50 | 14 |
| Net margin | -229.6% | -137.1% | 37 | 14 |
| Return on equity | -49.8% | -48.9% | 44 | 23 |
Peers (24): NGEN, ORMP, CUE, XGN, ACOG, NKTX, NAUT, ALEC, ELDN, MSLE, CNTN, CHRS, PYXS, ORGO, TRDA, MDWD, IPHA, DTIL, WHWK, CMPX, ANTX, AVXL, ALXO, PLX. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ADAG: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ADAG on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ADAG for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.